Collaborations Facilitated by China Focus, a partnering conference jointly sponsored by the CUBIO Innovation Center and MyBioGate
Bayer and Systems Oncology, who met at China Focus @ JPM 2019, on September 15, 2020 entered an exclusive global license agreement for ERSO™ , a novel drug for breast cancer treatment.
On September 17, 2020 Dyadic announced a collaboration with Hengrui Medicine for biologic drug development, specifically Dyadic’s proprietary C1 gene expression platform. The two companies had met at China Focus @ JPM 2020. In an interview later in September, Rawson went into more detail about the platform and doing business with a Chinese company.